Memorial Sloan Kettering patents autophagy-lysosomal pathway inhibitors

AI Briefing

• – Memorial Sloan Kettering Cancer Center develops new autophagy-lysosomal pathway inhibitors for pancreatic cancer treatment.
• – The new compounds are four 4-aminoquinoline inhibitors of the autophagy-lysosomal pathway.
• – The autophagy-lysosomal pathway is a promising target for cancer treatment, including pancreatic ductal adenocarcinoma.